Histone Deacetylase Inhibitor Panobinostat Induces Clinical Responses with Associated Alterations in Gene Expression Profiles in Cutaneous T-Cell Lymphoma
Top Cited Papers
Open Access
- 15 July 2008
- journal article
- research article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 14 (14), 4500-4510
- https://doi.org/10.1158/1078-0432.ccr-07-4262
Abstract
Purpose: Histone deacetylase inhibitors can alter gene expression and mediate diverse antitumor activities. Herein, we report the safety and activity of the histone deacetylase inhibitor panobinostat (LBH589) in cutaneous T-cell lymphoma (CTCL) and identify genes commonly regulated by panobinostat.Keywords
All Related Versions
This publication has 42 references indexed in Scilit:
- Histone deacetylase inhibitors in cancer therapyExpert Opinion on Investigational Drugs, 2007
- Dimethyl sulfoxide to vorinostat: development of this histone deacetylase inhibitor as an anticancer drugNature Biotechnology, 2007
- Aggresome induction by proteasome inhibitor bortezomib and α-tubulin hyperacetylation by tubulin deacetylase (TDAC) inhibitor LBH589 are synergistic in myeloma cellsBlood, 2006
- Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL)Blood, 2006
- Anticancer activities of histone deacetylase inhibitorsNature Reviews Drug Discovery, 2006
- Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?Nature Reviews Cancer, 2006
- Bortezomib Mediates Antiangiogenesis in Multiple Myeloma via Direct and Indirect Effects on Endothelial CellsCancer Research, 2006
- Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray ExperimentsStatistical Applications in Genetics and Molecular Biology, 2004
- A modified staging classification for cutaneous T-cell lymphomaJournal of the American Academy of Dermatology, 2001
- The Orphan Receptor COUP-TFII Regulates G2/M Progression of Breast Cancer Cells by Modulating the Expression/Activity of p21WAF1/CIP1, Cyclin D1, and cdk2Biochemical and Biophysical Research Communications, 2000